SB 202190: A Selective p38 MAPK Inhibitor for Cancer & Inflammation Research

Executive Summary: SB 202190 is a pyridinyl imidazole compound that selectively inhibits p38α and p38β MAP kinases, with IC₅₀ values of 50 nM and 100 nM, respectively, by competitive ATP binding (APExBIO A1632). Its cell-permeable profile allows effective inhibition of MAPK signaling in cell-based and animal studies (Shapira-Netanelov et al., 2025). SB 202190 reduces phosphorylation of p38 MAPK substrates and pro-inflammatory cytokine expression in vitro. Preclinical models demonstrate its utility in dissecting tumor–stroma interactions, apoptosis, and neuroprotection. APExBIO supplies SB 202190 as a research-use-only inhibitor for biochemical and translational workflows.

Biological Rationale

p38 mitogen-activated protein kinases (MAPKs) are serine/threonine kinases central to cellular responses involving stress, inflammation, apoptosis, and proliferation. The p38 MAPK pathway is activated by environmental stressors, inflammatory cytokines, and growth factors. Dysregulation of p38 MAPK signaling contributes to cancer progression, inflammatory diseases, and neurodegeneration (Shapira-Netanelov et al., 2025). Inhibiting specific isoforms, such as p38α and p38β, enables precise modulation of downstream effectors without broadly affecting parallel MAPK cascades. This selectivity is critical for experimental dissection of the Raf–MEK–MAPK pathway and for developing targeted therapies (see: Tumor–Stroma Interactions—this article extends these mechanistic insights by providing quantitative benchmarks and workflow parameters).

Mechanism of Action of SB 202190

SB 202190 is a potent, ATP-competitive inhibitor that selectively targets p38α and p38β MAPKs. The compound binds to the ATP-binding pocket of p38 MAPK, preventing phosphorylation and activation of downstream substrate proteins. The IC₅₀ for p38α is 50 nM and for p38β is 100 nM, with a dissociation constant (K_d) of 38 nM (buffer, 25°C, pH 7.4) (APExBIO). SB 202190 does not significantly inhibit p38γ, p38δ, or unrelated kinases at these concentrations. The inhibitor is cell-permeable, allowing effective use in live-cell assays and animal models. By blocking p38 MAPK activity, SB 202190 reduces phosphorylation of substrates such as MAPKAPK2 and CREB, and decreases expression of cytokines (e.g., IL-6, TNF-α) in stimulated cells. This mechanism underlies its broad utility in inflammation, apoptosis, and memory-associated research.

Evidence & Benchmarks

• SB 202190 inhibits p38α and p38β kinase activity with IC₅₀ values of 50 nM and 100 nM, respectively, in biochemical assays (APExBIO Product Data).
• The inhibitor reduces phosphorylation of p38 substrates and pro-inflammatory cytokine secretion (IL-6, TNF-α) in LPS-stimulated cell culture models (Shapira-Netanelov et al., 2025).
• In patient-derived gastric cancer assembloid models, SB 202190 modulates tumor–stroma interactions and drug response by altering MAPK-driven gene expression (DOI).
• SB 202190 is used in apoptosis assays to induce and quantify cell death in cancer cell lines, revealing its utility in dissecting regulated cell death pathways (see: Decoding Regulated Cell Death—this article updates with quantitative results from assembloid systems).
• In animal models of vascular dementia, SB 202190 reduces neuronal apoptosis and improves cognitive function, supporting its neuroprotective potential (APExBIO).

Applications, Limits & Misconceptions

SB 202190 is widely used to interrogate the p38 MAPK signaling pathway in cancer, inflammation, and neurobiology. Its high selectivity and potency make it suitable for these key applications:

• Inflammation research: Suppresses cytokine expression and inhibits inflammatory signaling.
• Cancer therapeutics research: Dissects tumor–stroma interactions and drug resistance in assembloid and organoid models.
• Apoptosis assay: Enables quantitative measurement of regulated cell death.
• Vascular dementia model: Provides neuroprotective effects by reducing neuronal apoptosis.

SB 202190 is supplied by APExBIO as a solid (A1632), soluble in DMSO (≥57.7 mg/mL) and ethanol (≥22.47 mg/mL), but insoluble in water. Recommended stock solutions are >10 mM in DMSO, with warming at 37°C or ultrasonic treatment for optimal solubility (product details).

Common Pitfalls or Misconceptions

• Non-selectivity for other kinases: SB 202190 shows minimal activity against p38γ/δ and unrelated kinases at recommended concentrations, but off-target effects may occur at excessive doses.
• Long-term solution storage: SB 202190 solutions are not recommended for long-term storage due to hydrolysis; prepare fresh aliquots for reproducibility.
• Solubility in aqueous buffers: The compound is insoluble in water; always use DMSO or ethanol as solvents for experimental consistency.
• Not a clinical drug: SB 202190 is for research use only and is not approved for therapeutic applications in humans.
• p38 MAPK-independent effects: At supra-physiological concentrations, non-specific effects may be observed; always titrate for pathway specificity.

Workflow Integration & Parameters

For biochemical assays, dissolve SB 202190 in DMSO to a stock concentration of >10 mM. For cell-based studies, dilute to working concentrations (typically 1–20 μM) in culture medium containing ≤0.1% DMSO (APExBIO). For animal models, administer via established routes (e.g., intraperitoneal injection) and monitor for toxicity. Store solid compound at -20°C; avoid repeated freeze-thaw cycles.

Researchers using assembloid or organoid systems can leverage SB 202190 to parse tumor–stroma signaling, as demonstrated in advanced gastric cancer models (Shapira-Netanelov et al., 2025). For the latest mechanistic insights and strategic guidance, see the article SB 202190 and the Future of Precision MAPK Pathway Inhibition, which this article extends by benchmarking SB 202190 in complex co-culture and assembloid platforms.

Conclusion & Outlook

SB 202190 (A1632, APExBIO) is a validated, highly selective p38α/β MAPK inhibitor enabling precision research in cancer, inflammation, and neurobiology. Its robust inhibition profile, cell permeability, and compatibility with 3D disease models position it as a standard tool for dissecting the MAPK signaling pathway and developing next-generation targeted therapies. Future work will expand its use in personalized drug screening and mechanism-driven discovery, especially in patient-derived assembloid systems.